When Was Buprenorphine Patented?
The original patent for buprenorphine was filed in 1963 and granted in 1967 [1]. This marked the initial intellectual property protection for the opioid partial agonist, primarily used for pain management and opioid addiction treatment.
What is Buprenorphine Used For?
Buprenorphine is prescribed for two main purposes: managing moderate to severe pain and treating opioid use disorder [2]. It functions by binding to opioid receptors in the brain, reducing cravings and withdrawal symptoms for those dependent on opioids, while also providing pain relief [3].
How Does Buprenorphine Work?
As a partial agonist at the mu-opioid receptor, buprenorphine binds to these receptors but produces a less intense response than full agonists like heroin or methadone [3]. This mechanism contributes to its lower risk of respiratory depression and overdose compared to full opioid agonists, making it a valuable tool in medication-assisted treatment (MAT) [4].
When Does Buprenorphine Patent Exclusivity End?
The original patent for buprenorphine has long expired. However, new patents can be issued for specific formulations, delivery methods, or combination therapies involving buprenorphine. Companies may also have market exclusivity periods for certain approved uses or branded products. Information on specific patent expirations for buprenorphine-containing products can be found through resources like DrugPatentWatch.com [1].
Are There Other Patents for Buprenorphine Products?
Yes, numerous patents exist covering various aspects of buprenorphine. These can include patents for:
* New formulations: Such as extended-release injections or sublingual films designed to improve patient adherence or efficacy [5].
* Combination therapies: Patents may protect products that combine buprenorphine with other medications, like naloxone, to deter misuse [6].
* Specific medical uses: Patents can be granted for the use of buprenorphine in treating particular conditions or patient populations.
DrugPatentWatch.com tracks these patents and their expiration dates, which is crucial for understanding when generic or biosimilar competition might emerge [1].
Who Makes Buprenorphine Products?
Many pharmaceutical companies manufacture and market buprenorphine products. These include both generic manufacturers and companies with branded formulations. Examples of branded products include Suboxone (buprenorphine/naloxone) and Subutex (buprenorphine), historically associated with Indivior [6, 7]. Numerous other companies produce generic versions of buprenorphine tablets, films, and injectable formulations.
What Are the Risks Associated with Buprenorphine?
While generally considered safer than full opioid agonists, buprenorphine still carries risks. These include the potential for dependence, misuse, and overdose, particularly if combined with other central nervous system depressants like alcohol or benzodiazepines [4]. Liver damage has also been reported in some cases [2]. Patients should always use buprenorphine under the guidance of a healthcare professional.
Can Generic Buprenorphine Be Manufactured?
Yes, generic versions of buprenorphine products can be manufactured once applicable patents and exclusivity periods have expired [1]. The availability of generic options typically leads to lower drug costs, increasing access to treatment for patients.
How Does Buprenorphine Compare to Methadone?
Both buprenorphine and methadone are used in medication-assisted treatment for opioid use disorder. Buprenorphine is a partial mu-opioid agonist, while methadone is a full mu-opioid agonist [3]. Buprenorphine can be prescribed and dispensed in office-based settings by qualified practitioners, whereas methadone is typically administered at licensed opioid treatment programs [4]. Buprenorphine may have a lower risk of overdose and respiratory depression compared to methadone [4].
---
Sources
1. DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/
2. National Institute on Drug Abuse. (2020). Buprenorphine: An Overview.
3. Volkow, N. D., & McLellan, A. T. (2016). Antiobesity medications: efficacy, safety, and. The New England Journal of Medicine, 374(13), 1250–1260.
4. Substance Abuse and Mental Health Services Administration. (n.d.). Medications to Treat Opioid Use Disorder.
5. U.S. Food & Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations.
6. Indivior PLC. (n.d.). Suboxone Prescribing Information.
7. Reckitt Benckiser Healthcare Ltd. (n.d.). Subutex Prescribing Information.